Peer-Reviewed Publications

    Gene expression profiling in respiratory tissues from rats exposed to mainstream cigarette smoke

    Gebel, S.; Gerstmayer, B.; Bosio, A.; Haussmann, H.-J.; Van Miert, E.; Müller, T.
    Published
    Feb 1, 2004
    DOI
    10.1093/carcin/bgg193
    PMID
    14578158
    Link to publication
    Topic
    Summary

    Cigarette smoke (CS) is known to cause cancer and other diseases, but little is known about the global molecular and cellular changes that occur prior to the appearance of clinically detectable symptoms. Using DNA microarrays covering 2031 cDNA probes, we investigated differential gene expression in tissues of the rat respiratory tract, i.e. respiratory nasal epithelium (RNE) and lungs of rats exposed either acutely (3 h) or subchronically (3 h/day, 5 days/week, 3 weeks) to mainstream CS with death either immediately or at 20 h after exposure. Differential gene expression was most evident in RNE of rats exposed once and was characterized by strong up-regulation of genes encoding oxidative stress-responsive and Phase II drug-metabolizing enzymes, such as haem oxygenase-1 and NAD(P)H:quinone oxidoreductase, which are all, at least in part, transcriptionally regulated by NF-E2-related factor 2 (Nrf2). After 3 weeks of exposure, the strength of expression of this class of genes was markedly reduced, pointing to an adaptive response. The generally lower response in the lungs of exposed rats is indicative of a deposition gradient of active smoke constituents from the upper to the lower respiratory tract. In sharp contrast to the CS-induced expression of oxidative stress and Phase II-responsive genes, induction of the genes encoding the Phase I drug-metabolizing enzymes cytochrome P450 (CYP)1A1 and aldehyde dehydrogenase-3 was not reduced after 3 weeks of exposure and was similarly high in lungs and RNE. Gene expression patterns in rats allowed to recover for 20 h showed that the CS-induced transcriptional changes observed immediately after exposure returned almost completely to normal, even after 3 weeks of repeated CS exposure. In general, these results demonstrate that CS induces a specific differential gene expression pattern in vivo, which may be instrumental in identifying the molecular mechanisms leading to the onset of inflammatory and/or morphological changes.

    Related Publications

    Verification Of Systems Biology Research In The Age Of Collaborative- Competition

    Systems Toxicology

    Verification Of Systems Biology Research In The Age Of Collaborative- Competition: Biological Network Models

    Systems Toxicology

    Verification of systems biology research in the age of collaborative competition

    Systems Toxicology

    An In Vitro Systems Toxicology Assessment of Novel Electronic Vapor Device by Using Air–Liquid Interface Buccal, Bronchial, Small Airway, and Alveolar Culture Models

    Systems Toxicology

    Community-Reviewed Biological Network Models for Toxicology and Drug Discovery Applications

    Systems Toxicology

    Verification Of Systems Biology Research In The Age Of Collaborative - Competition

    Systems Toxicology

    Verification Of Systems Biology Research In The Age Of Collaborative- Competition

    Systems Toxicology

    Verification Of Systems Biology Research In The Age Of Collaborative- Competition: Biological Network Models

    Systems Toxicology

    Verification of systems biology research in the age of collaborative competition

    Systems Toxicology

    An In Vitro Systems Toxicology Assessment of Novel Electronic Vapor Device by Using Air–Liquid Interface Buccal, Bronchial, Small Airway, and Alveolar Culture Models

    Systems Toxicology

    Community-Reviewed Biological Network Models for Toxicology and Drug Discovery Applications

    Systems Toxicology

    Verification Of Systems Biology Research In The Age Of Collaborative - Competition

    Systems Toxicology

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.